MJN110 (i.p.; 0.0818 mg/kg; twice daily for 5.5 days) reverses chronic constriction injury (CCI)-induced mechanical allodynia and thermal hyperalgesia in a dose-dependent manner. The respective ED50 value (95% confidence limits) is 0.430 (0.233-0.793) mg/kg[1]. Animal Model: Male C57BL/6J mice ranged from 18 to 35 g[1] Dosage: 0.0818 mg/kg Administration: I.p.; twice daily for 5.5 days Result: Reversed CCI-induced mechanical allodynia and thermal hyperalgesia in a dose-dependent manner.
In Vitro
Kinase Assay
Cell Assay
Animal Administration
References
[1]. Wilkerson JL, et al. The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model. J Pharmacol Exp Ther. 2016 Apr;357(1):145-56.
[2]. Habib A, et al. Inhibition of monoacylglycerol lipase, an anti-inflammatory and antifibrogenic strategy in the liver. Gut. 2018 Oct 9. pii: gutjnl-2018-316137.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
